Pay in 4 interest-free payments of $6.24 Learn more
Ships within 48 hours · Estimated delivery Oct 28 - Nov 2
Immediate medical attention is required if any of the following occur: Severe, persistent abdominal pain, particularly if radiating to the back (possible pancreatitis) Persistent vomiting preventing fluid intake for more than 24 hours Signs of dehydration: dark urine, dizziness, reduced urination, extreme thirst Symptoms of gallbladder disease: right upper abdominal pain, fever, jaundice Allergic reactions: rash, difficulty breathing, facial swelling For people with diabetes: worsening vision or diabetic retinopathy symptoms Symptoms of hypoglycaemia: shakiness, confusion, sweating, rapid heartbeat Pregnancy or suspected pregnancy (Wegovy is contraindicated in pregnancy) Patients should contact their GP or prescriber within a few days if they experience: Intolerable nausea or vomiting that persists beyond the first week of a new dose Severe constipation unresponsive to dietary changes and over-the-counter remedies Persistent diarrhoea lasting more than a few days Unusual or concerning weight loss patterns Mood changes, depression, or suicidal thoughts Thyroid symptoms: persistent hoarseness, lump in the neck, difficulty swallowing Concerns about medication interactions Routine follow-up appointments should be scheduled at regular intervals during re-titration, typically: Before restarting treatment (baseline assessment) After 8-12 weeks (mid-titration review) After reaching maintenance dose Every 3-6 months thereafter for ongoing monitoring These appointments allow monitoring of weight loss progress, assessment of side effects, review of dietary and lifestyle modifications, and evaluation of cardiovascular risk factors
Weight loss - GLP-1 agonists could also be considered for weight loss even in the absence of type 2 diabetes
Getting coverage approved requires understanding your plans specific requirements, providing thorough documentation, and knowing how to appeal if initially denied
Patients who adhere to a semaglutide weight loss program often see better overall health and sustained weight loss results
In another trial, patients who reduced their Zepbound dose to a lower 5 mg maintenance dose also preserved much of their earlier weight reduction compared with those who stopped treatment entirely
Age-related cognitive dysfunction and behaviour problems in dogs and cats
